Pinealon – 10mg
$49.97
Pinealon
is a synthetic bioregulatory tripeptide consisting of the short amino acid sequence Glu-Asp-Arg (Glutamic Acid-Aspartic Acid-Arginine). Developed as a targeted short-chain peptide (cytomedin), it is engineered to cross the blood-brain barrier and interact directly with the epigenetic structures of central nervous system tissues. Pinealon acts as a cell-specific genomic modulator that stimulates functional protein synthesis inside cerebral cortex cells and neurons, making it a prominent compound in neurogerontology, chronobiology, and cognitive research for investigating neurogenesis and the mitigation of cellular aging.
Key Features & Characteristics
- Mechanism of Action: Interacts directly with specific DNA promoter regions to reverse the epigenetic silencing of genes associated with cellular repair and survival.
- Blood-Brain Barrier Penetration: Ultra-low molecular weight structure allows it to bypass restrictive cellular barriers effortlessly without structural degradation.
- Neuroprotective Dynamics: Enhances cell viability in brain tissues by lowering free radical accumulation and stabilizing intracellular metabolic processes.
- Physical Form: Produced via high-fidelity chemical synthesis and supplied as a highly stable, white lyophilized powder ready for precise fluid reconstitution.
Primary Research Applications
- Cognitive Enhancement & Neuroplasticity: Extensively studied in animal models to observe changes in learning speed, memory retention accuracy, and overall behavioral adaptation under stress.
- Circadian Rhythm Integration: Investigated for its ability to optimize pineal gland interaction, normalize endogenous melatonin production, and restore fractured sleep-wake cycles.
- Neurogerontology & Senescence: Evaluated in aging neurological assays to track the reversal of age-dependent functional decline, intellectual degradation, and neuronal apoptosis.
For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.
99 in stock
Reviews
There are no reviews yet.